Jennifer Bath, Ph.D.
Chief Executive Officer and President
Jennifer holds a Ph.D. in Cellular and Molecular biology from North Dakota State University, and a Bachelor’s degree in Biology, with an emphasis on human genetics, from the University of Kansas. She began her career in academia, and moved into industry after a 15-year appointment as an Associate Professor of Cellular and Molecular Biology at Concordia College, Moorhead, Minnesota. She was the Founder and Executive Director of the Concordia College Global Vaccine Institute; whose mission is to prevent and treat neglected tropical diseases. Jennifer has broad experience in vaccine and therapeutic design, development and testing.
Dr. Bath served many guidance roles in industry including advising on the Economic Development Corporation’s Strategic Planning Initiatives, consulting biotechnology and pharmaceutical companies on strategic and operational business practices, and providing governance for workshops in technology entrepreneurship. She has established relationships with leaders in the fields of therapeutics and vaccinology, enhancing collaborative developments and partnerships in discovery.
Jennifer served in an executive role at Aldevron, LLC, as the Global Director of Client Relations, where she held both strategic and technical roles. She headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and the market. In addition, she served as a key technical specialist, particularly for therapeutic antibody discovery, and was responsible for retention and growth of the existing client base through individual efforts and efforts of the management team to deliver profitable, quality services.
Chief Financial Officer
Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. Currently, she serves on the board of directors for HealthyDakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committees. Prior to joining the executive team, Lisa served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.
Chief Technology Officer
As the Chief Technology Officer of ImmunoPrecise Antibodies, Chip Wheelock is responsible for overseeing all information technology aspects of ImmunoPrecise Antibodies. Mr. Wheelock works closely with the other members of the Executive Management team and unit business leaders to grow the company through the use of software and technology services. Using an active and practical approach, Mr. Wheelock directs all employees in the Information Technology departments to attain the company’s strategic goals and establishes the company’s information technology strategic plan.
Mr. Wheelock oversees all aspects of Information Technology where he provides leadership for continuous innovation of a wide array of technological systems across all of ImmunoPrecise’s businesses. He works closely with the individual business leaders to ensure that the technology and collaboration systems increase efficiencies and focuses on creating a competitive advantage through the innovative use of technology. Mr. Wheelock brings a diverse background to ImmunoPrecise, he has held leadership positions within the software development and services industries over the past 25 years encompassing global ERP deployments, cloud transformations and building strategic line of business applications. Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, most recently as a Senior Global Technical Account Manager, where he drove both strategic and technical initiatives for many large organizations. Chip holds a Bachelor’s degree from the University of Kansas along with several industry and project management certifications.
VP of Client Relations and Project Management
Kari Graber serves as the VP of Client Relations and Project Management for ImmunoPrecise Antibodies and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Kari served at Aldevron LLC where she held a client relations management role for their antibody services platform. Kari holds a Bachelor of Science in Food Science & Technology with a Minor in Microbiology from North Dakota State University.
VP of Operations
Jason Orloske serves as the Vice President of Operations for ImmunoPrecise and is responsible for operationalizing strategic initiatives and helping drive growth. Jason is a transformational business leader with almost 20 years’ experience in project portfolio management and strategic delivery. He partners with executives and senior management teams to completely uncover challenges and opportunities being faced, and develops a right-sized strategy that aligns with organizational vision.
Jason brings a diverse background to ImmunoPrecise. Much of his career has been spent in the consulting space focused on creating operational efficiencies and mergers and acquisitions. Most recently, Jason lead implementation management at WEX Health (health benefits SaaS platform), and Aldevron where he managed the project management office (PMO). Jason holds a master’s degree in Project Management from the University of Mary in Bismarck, ND, where he also taught as an adjunct professor for two years after graduation.